<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="options Respiratory syncitial virus 1â€&quot;50 11â€&quot;47 S, C, D Pavilizumab" exact="Ribavirin" post="aerosol Influenza 1.3â€&quot;40 8â€&quot;28 S, D Seasonal influenza immunization"/>
 <result pre="S, C ND Parainfluenza virus 3â€&quot;27 10â€&quot;50 S, A, D" exact="Ribavirin" post="Cidofovir Bocavirus 1â€&quot;3 Not reported S, C, D ND"/>
 <result pre="C ND Parainfluenza virus 3â€&quot;27 10â€&quot;50 S, A, D Ribavirin" exact="Cidofovir" post="Bocavirus 1â€&quot;3 Not reported S, C, D ND Adenovirus"/>
 <result pre="significant reduction in the progression from URTI to LRTI [5]." exact="Ribavirin" post="has been proven effective in hindering the progression from"/>
 <result pre="70 to 35%) in onco-hematological patients [5]. The lack of" exact="ribavirin" post="aerosol therapy has increased the risk of mortality in"/>
 <result pre="increased the risk of mortality in patients with HSCT [49];" exact="ribavirin" post="aerosol is the only approved treatment for severe RSV-related"/>
 <result pre="myeloma, routine treatment of RSV infection is not recommended [13]." exact="Ribavirin" post="therapy is recommended in patients with leukemia and patients"/>
 <result pre="HSCT at high risk of complications [5]. The co-administration of" exact="ribavirin" post="with intravenous immunoglobulins (IVIG), with specific anti-RSV immunoglobulins or"/>
 <result pre="neither intravenous administration of immunoglobulins nor the use of aerosol" exact="ribavirin" post="are useful strategies for the effective reduction of the"/>
 <result pre="required [43]. Promising results following the use of IVIG and" exact="ribavirin" post="have been obtained in vitro; however, these data have"/>
 <result pre="vitro regarding the use of antiviral drugs such as cidofovir," exact="ganciclovir" post="and other antiretroviral drugs (zalzitabine, alovudine, stavudine) but there"/>
 <result pre="but there are not as many validations in vivo [48]." exact="Cidofovir" post="has been shown to reduce mortality, but it is"/>
 <result pre="the application of this measure [29]. The use of aerosol" exact="ribavirin" post="and pavilizumab as preventive strategies in patients with URTI"/>
 <result pre="in lymphopenic patients [48]. Regarding PiV, the real impact of" exact="ribavirin" post="and of experimental anti-viral agents such as DAS 181"/>
 <result pre="occurs in immunocompromised patients. Retrospective studies demonstrate positive outcomes with" exact="ribavirin" post="(alone or in combination with immunomodulators) for the treatment"/>
 <result pre="hematopoietic cell transplant recipientsBr J Haematol2008143445546710.1111/j.1365-2141.2008.07295.x18785968 49.ShahDPet al.Impact of aerosolized" exact="ribavirin" post="on mortality in 280 allogeneic haematopoietic stem cell transplant"/>
</results>
